GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santarus, Inc. (FRA:TW4A) » Definitions » FCF Yield %

Santarus, (FRA:TW4A) FCF Yield % : 0.00 (As of May. 19, 2024)


View and export this data going back to . Start your Free Trial

What is Santarus, FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Santarus,'s Trailing 12-Month Free Cash Flow is €61.7 Mil, and Market Cap is €1,548.5 Mil. Therefore, Santarus,'s FCF Yield % for today is 0.00%.

The historical rank and industry rank for Santarus,'s FCF Yield % or its related term are showing as below:


FRA:TW4A's FCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -14.14
* Ranked among companies with meaningful FCF Yield % only.

Santarus,'s FCF Margin % for the quarter that ended in Sep. 2013 was 32.76%.


Santarus, FCF Yield % Historical Data

The historical data trend for Santarus,'s FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santarus, FCF Yield % Chart

Santarus, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.62 13.20 -16.57 - 5.17

Santarus, Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.85 6.72 -0.17 10.58 8.37

Competitive Comparison of Santarus,'s FCF Yield %

For the Biotechnology subindustry, Santarus,'s FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santarus,'s FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santarus,'s FCF Yield % distribution charts can be found below:

* The bar in red indicates where Santarus,'s FCF Yield % falls into.



Santarus, FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Santarus,'s FCF Yield % for the fiscal year that ended in Dec. 2012 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=26.637 / 515.5986015
=5.17%

Santarus,'s annualized FCF Yield % for the quarter that ended in Sep. 2013 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=24.21 * 4 / 1156.825769
=8.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santarus, FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Santarus, FCF Yield % Related Terms

Thank you for viewing the detailed overview of Santarus,'s FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Santarus, (FRA:TW4A) Business Description

Traded in Other Exchanges
N/A
Address
Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.

Santarus, (FRA:TW4A) Headlines

No Headlines